Patents by Inventor Wayne David Kohn

Wayne David Kohn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oxyntomodulin peptide analogue
    Patent number: 8415296
    Abstract: The present invention provides Oxyntomodulin peptide analogues useful in the treatment of diabetes and/or obesity.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: April 9, 2013
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Wayne David Kohn
  • Oxyntomodulin peptide analogue
    Patent number: 8367607
    Abstract: The present invention provides an Oxyntomodulin peptide analogue useful in the treatment of diabetes and/or obesity.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: February 5, 2013
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Wayne David Kohn
  • OXYNTOMODULIN PEPTIDE ANALOGUE
    Publication number: 20110152181
    Abstract: The present invention provides Oxyntomodulin peptide analogues useful in the treatment of diabetes and/or obesity.
    Type: Application
    Filed: December 15, 2010
    Publication date: June 23, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Jorge ALSINA-FERNANDEZ, Wayne David KOHN
  • OXYNTOMODULIN PEPTIDE ANALOGUE
    Publication number: 20110152182
    Abstract: The present invention provides an Oxyntomodulin peptide analogue useful in the treatment of diabetes and/or obesity.
    Type: Application
    Filed: December 15, 2010
    Publication date: June 23, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Jorge Alsina-Fernandez, Wayne David Kohn
  • Pegylated PTH as PTH receptor modulators and uses thereof
    Patent number: 7820179
    Abstract: Pharmaceutical compositions and methods are provided for the treatment and prevention of bone loss diseases including osteoporosis in a mammal.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: October 26, 2010
    Assignee: Eli Lilly and Company
    Inventors: Patricia Lea Brown-Augsburger, Wayne David Kohn
  • CYCLIC PEPTIDE CXCR4 ANTAGONISTS
    Publication number: 20100130409
    Abstract: Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection.
    Type: Application
    Filed: January 25, 2010
    Publication date: May 27, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Wayne David Kohn, Sheng-Bin Peng, Liang Zeng Yan
  • Cyclic peptide CXCR4 antagonists
    Patent number: 7691813
    Abstract: Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection.
    Type: Grant
    Filed: May 20, 2008
    Date of Patent: April 6, 2010
    Assignee: Eli Lilly and Company
    Inventors: Wayne David Kohn, Sheng-Bin Peng, Liang Zeng Yan
  • PEGYLATED PTH AS PTH RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20090253630
    Abstract: Pharmaceutical compositions and methods are provided for the treatment and prevention of bone loss diseases including osteoporosis in a mammal.
    Type: Application
    Filed: October 4, 2007
    Publication date: October 8, 2009
    Inventors: Patricia Lea Brown-Augsburger, Wayne David Kohn
  • Extended glucagon-like peptide-1 analogs
    Patent number: 7482321
    Abstract: The invention encompasses GLP-1 peptides with modifications at various positions coupled with an extended C-terminus that provides increased stability.
    Type: Grant
    Filed: January 3, 2003
    Date of Patent: January 27, 2009
    Assignee: Eli Lilly and Company
    Inventors: Wolfgang Glaesner, Wayne David Kohn, Rohn Lee Millican, Lianshan Zhang
  • CYCLIC PEPTIDE CXCR4 ANTAGONISTS
    Publication number: 20080300177
    Abstract: Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection.
    Type: Application
    Filed: May 20, 2008
    Publication date: December 4, 2008
    Inventors: Wayne David Kohn, Sheng-Bin Peng, Liang Zeng Yan
  • Cyclic peptide CXCR4 antagonists
    Patent number: RE42274
    Abstract: Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: April 5, 2011
    Assignee: Eli Lilly and Company
    Inventors: Wayne David Kohn, Sheng-Bin Peng, Liang Zeng Yan